Latigo Biotherapeutics, Inc. Common Stock (LTGO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Latigo Biotherapeutics, Inc. Common Stock (LTGO) has a cash flow conversion efficiency ratio of 0.107x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-27.07 Million) by net assets ($-252.58 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. View today's stock price for Latigo Biotherapeutics, Inc. Common Stoc for real-time trading data and today's change.
Latigo Biotherapeutics, Inc. Common Stock - Cash Flow Conversion Efficiency Trend (2024–2025)
This chart illustrates how Latigo Biotherapeutics, Inc. Common Stock's cash flow conversion efficiency has evolved over time, based on yearly financial data. Also see LTGO market cap overview for the company's overall valuation and market capitalisation.
Latigo Biotherapeutics, Inc. Common Stock Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Latigo Biotherapeutics, Inc. Common Stock ranked by their cash flow conversion efficiency. Also see LTGO current and non-current assets for a full breakdown of the balance sheet.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Leshan Giantstar Farming & Husbandry Corp Ltd
SHG:603477
|
0.132x |
|
Sichuan Haite High-tech Co Ltd
SHE:002023
|
0.002x |
|
ZYNP Corp
SHE:002448
|
0.008x |
|
Xinjiang Communications Construction Group Co Ltd Class A
SHE:002941
|
0.089x |
|
BioPharma Credit PLC
LSE:BPCR
|
0.029x |
|
Goldman Sachs BDC Inc
NYSE:GSBD
|
0.020x |
|
Sitronix Technology Corp
TW:8016
|
0.064x |
|
Prospect Capital Corporation
NASDAQ:PSEC
|
0.022x |
Annual Cash Flow Conversion Efficiency for Latigo Biotherapeutics, Inc. Common Stock (2024–2025)
The table below shows the annual cash flow conversion efficiency of Latigo Biotherapeutics, Inc. Common Stock from 2024 to 2025. Review Latigo Biotherapeutics, Inc. Common Stoc financial flexibility index to assess the company's free cash flow relative to its total liabilities.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-231.67 Million | $-97.56 Million | 0.421x | +7.10% |
| 2024-12-31 | $-129.60 Million | $-50.95 Million | 0.393x | -- |
About Latigo Biotherapeutics, Inc. Common Stock
Latigo Biotherapeutics, Inc. develops non-opioid pain medicines designed to stop the transmission of pain without the risk of addiction. The company's pipeline includes LTG-001, an oral NaV1.8 inhibitor designed to provide fast-acting, opioid-sparing relief for the treatment of acute pain; LTG-321, a NaV1.8 inhibitor candidate developed for the treatment of chronic musculoskeletal pain, starting … Read more